Variant glycosylation: an underappreciated regulatory mechanism for β1 integrins  by Bellis, Susan L
www.bba-direct.com
Biochimica et Biophysica Acta 1663 (2004) 52–60Review
Variant glycosylation: an underappreciated regulatory mechanism
for h1 integrins
Susan L. Bellis*
Department of Physiology and Biophysics, University of Alabama at Birmingham, MCLM 982A, 1918 University Boulevard, Birmingham, AL 35294, USAReceived 3 February 2004; received in revised form 24 March 2004; accepted 31 March 2004
Available online 20 April 2004Abstract
Although it has been known for many years that h1 integrins undergo differential glycosylation in accordance with changes in cell
phenotype, the potential role of N-glycosylation as a modulator of integrin function has received little attention. One reason for the relatively
limited interest in this topic likely relates to the fact that much of the prior research was correlative in nature. However, new results now
bolster the hypothesis that there is a causal relationship between variant glycosylation and altered integrin activity. In this review, the evidence
for variant glycosylation as a regulatory mechanism for h1 integrins are summarized, with particular emphasis on: (1) outlining the instances
in which cell phenotypic variation is associated with differential h1 glycosylation, (2) describing the specific alterations in glycan structure
that accompany phenotypic changes and (3) presenting potential mechanisms by which variant glycosylation might regulate integrin function.
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1. Introduction Much of the work aimed at understanding integrin regu-
lation has focused on functional changes that are induced byThe activity of integrin adhesion receptors is essential for
normal cellular function and survival. The binding of
integrins to protein ligands present within the extracellular
matrix, or expressed on the surface of other cells, leads to
the activation of intracellular signaling cascades that ulti-
mately regulate diverse processes such as embryogenesis,
wound healing, and tumorigenesis [1–4]. Because of the
importance of integrins in human biology and disease,
substantial effort has been directed at understanding the
regulation of these receptors.
Integrins are heterodimeric transmembrane glycoproteins
composed of a and h subunits. There are multiple a and h
species, and the pairing of these species determines the
specificity of the integrin for ligand. The h1 integrin subunit
is ubiquitously expressed, and is known to pair with at least
12 different a subunits [5]. Some of the more widely
expressed h1-containing heterodimers include a5h1 and
a6h1, which are selective for fibronectin and laminin,
respectively, as well as a2h1 and a3h1, both of which
can bind multiple ligands including collagen and laminin.0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2004.03.012
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E-mail address: bellis@physiology.uab.edu (S.L. Bellis).the activation of intracellular signaling cascades (‘‘inside-out
signaling’’) [5,6]. In this model, signaling events trigger
some alteration in integrin cytoplasmic tails. These altera-
tions, in turn, either modulate integrin avidity through
clustering, or induce altered conformation in the extracellular
domain, leading to changes in integrin affinity for ligand.
Clearly, inside-out signaling represents an important mech-
anism for integrin regulation. However, in contrast to the
considerable attention currently focused on this model, the
potential role of altered glycosylation in modulating integrin
function has been largely ignored, despite the widespread
observation that cells express variant h1 glycoforms when
undergoing significant phenotypic changes. The principal
goal of this review is to summarize the evidence supporting
differential N-glycosylation as a regulatory mechanism,
particularly for integrins of the h1 subfamily.2. Variant B1 integrin glycoforms have been observed in
multiple cell types
Numerous studies spanning the last 15 years have
reported that cells express a h1 integrin isoform with
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marked change in cell phenotype [7–19]. Treatment of
integrins with N-glycan-cleaving enzymes prior to electro-
phoresis eliminated this mobility difference, suggesting that
mobility shifts were due to variability in the composition of
integrin N-linked carbohydrates. Differential h1 integrin
glycosylation occurs in conjunction with multiple processes
including keratinocyte activation [14], thymocyte matura-
tion [17], Sezary syndrome [20], myeloid differentiation
[7,10], cytotrophoblast invasiveness [16] and oncogenic
transformation or metastasis [8,11,13,15,21–23]. The find-
ing that variant h1 integrin glycoforms are expressed by
diverse cell types, under conditions that promote long-term
changes in cell adhesiveness and motility, lends strong
support for the supposition that variant glycoforms are
functionally important.
Intriguingly, the h1 integrin may be well positioned for
regulation by glycosylation. Unlike other integrin subunits,
partially glycosylated precursor h1 integrins form a stable
pool within the endoplasmic reticulum [24–27]. The cell,
therefore, may be able to direct the expression of a variantly
glycosylated species by recruiting precursors from the ER,
rather than requiring de novo synthesis of the polypeptide
backbone. Very little research has been directed at under-
standing the trafficking of h1 integrins from ER to Golgi,
however, this transition obviously represents a potential
target for regulation of h1 integrin cell surface expression.
Such a transition does appear to have physiologic relevance
in at least one instance; one of the early events in keratino-
cyte terminal differentiation involves a blockade in Golgi-
mediated h1 glycosylation, contributing ultimately to a loss
in cell surface h1-containing heterodimers [28].3. An altered B1 integrin carbohydrate profile most
commonly results from a change in B1-6 branching of
oligosaccharides, or in the degree of sialylation
Although future research will likely underscore the
importance of ER–Golgi trafficking in the regulation of
B1, most of the prior reports of variable B1 posttransla-
tional processing describe changes that occur within later
subcompartments of the Golgi. For example, differential
electrophoretic mobility is typically observed in the ‘‘ma-
ture’’ (Golgi-modified) integrin species, but not in the ER-
resident precursor, suggesting that core glycosylation does
not vary significantly in response to changes in cell
phenotype. Attempts to define the specific Golgi-mediated
modifications that contribute to differential mobility have
been limited, most probably due to the technical challenges
associated with the analysis of carbohydrate structures. A
few recent studies have employed either mass spectromet-
ric methods [29,30] or an HPLC mapping technique [31]
to determine that B1 integrins are elaborated with a
heterogeneous mixture of N-acetyllactosamine type multi-
antennary structures that are sometimes capped with thenegatively charged sugar, sialic acid (see Refs. [32–35] for
reviews of N-glycan biosynthesis). These data are in good
agreement with prior lectin analyses of integrin glycans
[9,21,23,31,36,37]. In general, the differential h1 glyco-
sylation observed during cell phenotypic variation seems to
result primarily from an altered abundance of sialic acids
or from increased h1-6 branching of N-linked oligosac-
charides [7,8,12,13,17,21,23,30,36,38].
The formation of a h1-6 branched structure is initiated by
GnT-V (h1-6 N-acetylglucosaminyltransferase V), a trans-
Golgi enzyme encoded by the Mgat 5 gene. GnT-V adds N-
acetylglucosamine to mannose in a h1-6 linkage, and the
resulting structure can subsequently be acted on by other
glycosyltransferases to form a poly-N-acetyllactosamine
chain (see Fig. 1 for clarification of oligosaccharide struc-
tures). The terminal galactose on the chain can either be left
unmodified, or capped with several sugars including sialic
acid. It follows that an increase in the total number of poly-
N-acetyllactosamine chains (due to the addition of the h1-6
branch) is often accompanied by a corresponding increase in
sialylation. Sialic acids are most commonly added to N-
linked glycans in an a2-3 linkage, but can also be added in
a2-6 or a2-8 linkages. Multiple sialyltransferases direct the
a2-3 linkage, whereas the a2-6 linkage is primarily medi-
ated by ST6Gal I (h-galactoside a2,6-sialyltransferase).
Another a2-6 sialyltransferase, ST6Gal II, has been identi-
fied; however, this enzyme acts preferentially on oligosac-
charides, as compared with N-linked glycoprotein glycans
[39,40].
While changes in h1-6 branching and/or sialic acid
abundance have been noted in several different cell types,
the most compelling data suggesting a functional role for
these alterations come from studies of tumorigenesis/metas-
tasis and immune cell behavior.4. Altered glycosylation of B1 integrins is prevalent in
tumor cells, and is associated with cell invasiveness and
metastasis
An altered profile of cell surface carbohydrates is a well-
accepted hallmark of malignant transformation (reviewed in
Refs. [41–47]). Aberrant N-glycosylation has long been
associated with tumor cell behaviors including altered
adhesiveness to extracellular matrix ligands, increased cell
motility/invasiveness, and anchorage-independent growth.
While a number of glycosyltransferases may participate in
these processes, evidence supporting the involvement of
GnT-V and ST6Gal I in tumorigenesis/metastasis are espe-
cially persuasive. Elevated expression and activity of these
enzymes have consistently been observed in oncogene-
expressing cell lines as well as in human neoplastic tissue.
Cell culture studies suggest that GnT-V is up-regulated by
src [48], her-2/neu [49], ras [50–54], Ets-1 [55,56], v-sis
[54] and polyoma middle T antigen [57,58], whereas
ST6Gal I is up-regulated by ras [8,50,59,60]. Animal studies
Fig. 1. Synthesis of representative complex N-linked oligosaccharides. [1] Within the ER, a pre-formed oligosaccharide is transferred from a lipid carrier to an
asparagine residue. [2] Glycosidases within the ER and Golgi remove glucoses and selected mannoses from the oligosaccharide precursor. [3a]
Glycosyltransferases within the medial/trans Golgi act sequentially to modify the trimannosyl core. The diagram depicts the addition of an N-acetyllactosamine
unit, which can be repeated (‘‘poly-N-acetyllactosamine’’). Following addition of these units, the terminal galactose on the chain can either be left unmodified,
or capped with sugars such as sialic acid. (Other types of modifications not shown here include fucosylation.) [3b] In some instances, additional poly-N-
acetyllactosamine chains are added. This addition is initiated by GnT-V, an enzyme that adds N-acetylglucosamine to mannose in a h1-6 linkage (forming a
‘‘h1-6 branch’’). (Note that a fourth chain can be added to the other mannose, generating a tetraantennary structure).
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metastasis [58,61–68]. For example, GnT-V-deficient trans-
genic mice experience attenuated tumor growth and metas-
tasis when challenged with a polyoma virus middle T
oncogene [58]. In humans, the activity and/or expression
of GnT-V and ST6Gal I are elevated in multiple types of
tumors [69–80], and high levels of these enzymes or their
cognate sugars are correlated with metastasis and a poor
patient prognosis [69,71,74,81–88]. Despite this wealth of
data implicating GnT-V and ST6Gal I in cancer progression,
our understanding of the molecular mechanisms linking
altered glycosylation to tumorigenesis/metastasis has been
limited by the lack of knowledge regarding the specific
substrates for these enzymes.
Accumulating evidence points to h1 integrins as an
important target for GnT-V and ST6Gal I. Increased levels
of h1-6 branching and sialylation are present on h1 integ-
rins expressed by several transformed cell types [8,21–23].
Our group has shown that stable transfection of oncogenic
ras in colon epithelial cells induces increased ST6Gal I
expression, and correspondingly, elevated a2-6 sialylation
of h1, but not h3 or h5, integrins [8]. Accordingly,
oncogenic ras-expressing cells demonstrate altered adhe-
siveness to h1 ligands such as collagen, but not to the h3/h5
ligand, vitronectin. This differential preference of ras-trans-
formed cells for selected integrin ligands could influence
many aspects of tumor cell behavior including cell recruit-
ment to, or survival within, novel matrix milieus.
Elevated a2-6 sialylation is particularly correlated with
changes in cell motility and invasiveness [89–93]. The
overexpression of ST6Gal I in mammary carcinoma cellsstimulates cell invasion through a fibronectin meshwork
[92], whereas invasion through Matrigel is markedly re-
duced in HT-29 colonocytes transfected with antisense
ST6Gal I [90]. Similar to the effects of ST6Gal I, forced
expression of GnT-V causes altered cell adhesion to the
substratum [65,94], increased haptotactic migration toward
fibronectin [94], and enhanced cell invasion through Matri-
gel [56,94]. In the latter investigations, it was not deter-
mined whether the overexpression of GnT-V was associated
with any changes in sialylation, an important consideration
given that poly-N-acetyllactosamine chains are acceptor
sites for sialic acid. The possibility that GnT-V mediates
at least some of its effects on cell behavior via increased
sialylation is a topic that merits further exploration.5. Altered sialylation of B1 integrins regulates immune
cell behavior
Another major area of investigation suggesting that
altered integrin glycosylation has functional relevance cen-
ters on studies of immune cell behavior. It is well known
that glycoconjugates regulate many aspects of leukocyte
function (reviewed in Refs. [95–97]), and sialyl Lewis
structures (which contain a2-3 linked sialic acids) are
important mediators of leukocyte/endothelial cell interac-
tions [98]. However, evidence implicating a2-6 linked sialic
acids in immune cell function is also mounting. Data from
our laboratory [7] suggest that variant a2-6 sialylation of h1
integrins regulates some aspects of myeloid differentiation
along the monocyte/macrophage lineage. Phorbol ester
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THP-1 myeloid cells induces down-regulation of ST6Gal I,
and correspondingly leads to the expression of hyposialy-
lated h1 integrins. The expression of hyposialylated h1
integrins is temporally correlated with elevated cell binding
to h1 integrin ligands such as fibronctin, and a U937 cell
variant that does not down-regulate ST6Gal I in response to
PMA does not exhibit PMA-dependent cell adhesiveness.
Further implicating sialylation as a direct modulator of
integrin function, we reported that the enzymatic de-sialy-
lation of purified a5h1 integrins significantly enhances
fibronectin-binding in a cell-free assay system. Thus, the
behavior of purified a5h1 integrins recapitulates that of
a5h1 integrins expressed on the myeloid cell surface;
integrins lacking sialic acids bind better to fibronectin.
Supporting our results, the enzymatic removal of sialic acids
from the surface of HL60 myeloid cells [99], MDCK cells
[100] and MDAY-D2 murine metastatic cells [101] stimu-
lates fibronectin binding to cell surface integrins, although
in one instance de-sialylation was reported to inhibit fibro-
nectin binding [12], a discrepancy not currently understood.
Final evidence suggesting that sialylation plays a causal role
in regulating integrin function has been provided by Villa-
vicencio-Lorini et al. [102]. In this study, HL60 myeloid
cells were engineered to express an unnatural variant of
sialic acid; the a5h1 and a4h1 integrins of these cells
displayed elevated binding activity.
Studies using genetically engineered mice unequivocal-
ly show that immune cell responses depend upon the
activity of ST6Gal I. ST6Gal I knock-out mice are
immunocompromised, primarily due to a defect in B cell
development [103]. However, an ST6Gal I-deficient (but
not null) mouse, generated by mutation of one of the
several ST6Gal I promoter sequences, demonstrates an
enhanced inflammatory response when challenged with a
bacterial pathogen [104]. These latter results fit our model
quite well; hyposialylated h1 integrins expressed by leu-
kocytes have better ligand binding activity, leading to
increased leukocyte adhesiveness (and therefore recruit-
ment to sites of inflammation).6. Potential mechanisms linking variant integrin
glycosylation to alterations in integrin function
Some of the earliest studies of h1 glycosylation fo-
cused on the relatively straightforward question of wheth-
er N-glycosylation was required for integrin activity. In
these studies, adhesion was examined in cells treated with
either tunicamycin, a reagent that prevents the addition of
glycans to asparagine residues by blocking the formation
of the lipid-linked oligosaccharide precursor, or with
compounds that inhibit mannosidase activity (e.g. swain-
sonine or deoxymannojirimycin). Results generated from
this type of approach strongly suggested that integrin
glycosylation was necessary for normal cell adhesionand spreading on integrin ligands [36,105–107], although
this has been disputed [108]. Further examination revealed
that at least some of the inhibitory effects of these
compounds (particularly tunicamycin) on integrin function
were due to impaired trafficking of integrins through the
Golgi [106], leading to a loss in cell surface receptors. N-
glycosylation was also reported to be essential for ah
subunit pairing [106]. As noted above, however, under
physiologic conditions, changes in integrin glycosylation
typically involve the more terminal carbohydrate struc-
tures added within the trans-Golgi (e.g. sialic acid or h1-6
branched chains). The presence or absence of these
glycans does not significantly affect integrin maturation
or cell surface expression; rather, these structures seem to
directly modulate integrin function.
The mechanisms that link altered glycosylation to altered
function have not been defined, although many mechanisms
can be speculated. One of the obvious possibilities is that N-
glycosylation influences protein conformation. Spatial con-
formation studies indicate that h1-6-linked poly-N-acetyl-
lactosamine chains bend back toward the protein rather than
extending into the extracellular milieu, implying that this
structure could interact with the polypeptide backbone
[109,110]. Other studies, based on NMR analyses, suggest
that glycosylation restricts dynamic fluctuations in protein
conformation [111–113]. This is due, at least in some cases,
to stabilizing interactions between the glycan and selected
amino acid residues [111,112]. Finally, exciting new work
from Luo et al. [114] provides very convincing evidence for
conformational regulation by N-glycans. In this study, an
asparagine residue was substituted for a proline in the h1
integrin subunit at amino acid #333. Upon expression in
CHO-K1 cells, this asparagine was N-glycosylated, and it
was elegantly shown that a5h1 integrins with these aber-
rantly glycosylated h1 subunits assumed an active ligand-
binding conformation. Although the introduction of an
asparagine residue at site 333 does not mimic any known
naturally occurring mutation, clearly these studies provide
proof of principal that altered glycosylation can affect
integrin conformation.
Another possibility is that the large size (or charge) of
N-glycans masks critical functional domains within the
integrin heterodimer. In fact, masking of peptide, or
particularly carbohydrate (e.g., galactose), epitopes is
thought to be one of the important functions of sialic acid
[96,115]. However, our research suggests that any rela-
tionship between sialic acid masking and integrin function
may be complex. We find that the enzymatic de-sialylation
of purified a1h1 integrins inhibits a1h1 binding to
collagen (the preferred ligand for this receptor), whereas
de-sialylation of a5h1 stimulates fibronectin binding [7,8].
Like a5h1, de-sialylated a3h1 integrins exhibit enhanced
ligand binding [30]. It is tempting to speculate that the
fundamental difference in the effects of sialylation on the
function of a1h1, versus a5h1 or a3h1, has something to
do with the fact that a1, but not a5 or a3, subunits have
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integrin ligands [116,117]. The h1 subunit has an ‘‘I-like’’
domain, and it is hypothesized that, in heterodimers
lacking I domain-containing a subunits, ligand binds
directly to the h1 I-like domain [116]. Conversely, in
heterodimers that have an a I domain, the conformation of
the h1 subunit is thought to allosterically regulate a I
domain/ligand interactions. Hence, the mechanisms regu-
lating ligand binding appear to be fundamentally different
for integrin heterodimers with and without I-domain-con-
taining a subunits. Surprisingly, the h1 integrin asparagine
residues that carry N-linked carbohydrates have not yet
been identified, so it is currently difficult to speculate how
altered sialylation (with the corresponding change in
negative charge) could affect integrin conformation and/
or ligand recognition. However, two of the 12 asparagine
residues that have consensus for N-glycosylation [118] lie
within the h1 integrin ‘‘I-like’’ domain, and therefore,
carbohydrate modifications at these sites would likely
affect ligand binding.
While results from purified integrin/ligand binding
assays suggest that carbohydrate moieties directly modu-
late ligand/receptor interactions, altered glycosylation
could affect integrin function via less direct mechanisms
as well. Variant glycosylation may alter the lateral associ-
ation of integrins with other membrane-associated proteins
that coordinately regulate downstream integrin-dependent
processes (for review of integrin-associated proteins, see
Ref. [119]). Some examples of membrane-associated pro-
teins that interact with the extracellular domain of integrins
include the urokinase-type plasminogen activation receptor,
uPAR, [120], and certain members of the tetraspanin
family [121,122]. Notably, the interaction between tetra-
spanin CD82 and the integrin heterodimers a3h1 or a5h1
appears to depend upon the glycosylation state of both
CD82 and the integrin species [123]. Similarly, glycosyl-
ation of a3h1 influences the formation of a complex
comprised of a3h1, the CD9 tetraspanin, and the GM3
glycosphingolipid [124].
N-glycosylation could also potentially regulate the as-
sociation between integrins and membrane glycolipids, and
thereby direct localization of integrins to plasma membrane
microdomains. It has been known for many years that
glycosphingolipids play some role in modulating cell
adhesiveness (reviewed in Refs. [125–127]), although
the molecular mechanisms underlying this phenomenon
are not well understood. Recently, Wang et al. [128]
reported that the glycosphingolipid, GT1b, binds directly
to a5h1, and subsequently alters the binding of this
integrin species to fibronectin. N-glycosylation of a5h1
is necessary for this interaction, as the enzymatic removal
of N-glycans from a5h1 blocked GT1b association. Com-
plementary studies suggested that the glycosylation of a3
and a5 subunits may regulate the translocation of these
integrins to glycosphingolipid-enriched plasma membrane
microdomains [129].Localization of integrins to specific subdomains may
depend upon the degree of h1-6 branching. Yamamoto et
al. [56] reported that a3h1 integrins with an elevated level
of h1-6 linked poly-N-acetyllactosamine chains (due to
forced expression of GnT-V) were targeted to the leading
lamellipodia of migratory glioma cells. It was not deter-
mined in this study whether elevated h1-6 branching was on
the a3 or h1 subunit. h1-6 linked poly-N-acetyllactosamine
structures may also regulate integrin clustering. In work
from Pierce’s group, transfection of GnT-V into fibrosarco-
ma cells caused increased h1-6 branching on h1 integrins,
and the acquisition of these structures was, in turn, associ-
ated with reduced a5h1 integrin clustering [94]. The a5
subunit of GnT-V-transfected cells did not carry h1-6
branched chains, suggesting that a5 is not a substrate for
this enzyme. Likewise, elevated h1-6 branching was ob-
served on h1, but not a5, integrins expressed by GnT-V-
transfected hepatocarcinoma cells [130]. These results,
combined with our results indicating that ST6Gal I modifies
h1, but not h3 or h5 integrins, highlight a concept that tends
to be underappreciated by those outside of the glycobiology
community, namely, that glycosyltransferases, particularly
those acting late in N-glycan synthesis, have a selected
substrate specificity, and may therefore regulate specific
cellular responses.7. Summary
The hypothesis that variant glycosylation represents an
important regulatory mechanism for h1 integrins is founded
on two general observations. First, the direct manipulation of
h1 glycosylation (via enzymatic methods or introducing
glycosylation sites through mutagenesis) clearly alters integ-
rin conformation and ligand-binding activity. These data
provide proof of principal that N-linked glycans modulate
integrin function. However, perhaps more importantly, there
is an impressive body of literature indicating that h1 integ-
rins undergo altered glycosylation in response to physiologic
cues. In light of these findings, it is reasonable to assume that
the altered cell adhesiveness and motility induced by events
such as cell differentiation or transformation are regulated, at
least in part, by the variant glycosylation of h1-containing
integrin heterodimers. In sum, the evidence supporting
variant glycosylation as a regulatory mechanism for h1
integrins are compelling, however, much work remains to
be done with regard to understanding the specific mecha-
nisms by which variant glycosylation regulates integrin
function. For example, identifying specific glycosylation
sites, as well as defining carbohydrate structures, would
allow a better understanding of how altered glycosylation
might affect integrin conformation or ligand recognition. In
addition to direct effects on integrin structure, there is a need
to evaluate the role of variant glycosylation in regulating
processes such as integrin subcellular localization or inter-
action with known integrin-associating proteins.
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